59
We report a case of reversible encephalopathy syndrome in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin.
 ( adverse event: undergoing ,  a 16-year-old girl with acute myelogenous leukemia (AML): Subject, 16-year-old: Subject.Age, girl: Subject.Gender, reversible encephalopathy syndrome: Effect, consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin: Treatment, acute myelogenous leukemia: Treatment.Disorder, idarubicin: Treatment.Drug, BH-AC: Treatment.Drug, idarubicin: Combination.Drug, BH-AC: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( adverse event: undergoing ,  a 16-year-old girl with acute myelogenous leukemia (AML): Subject, 16-year-old: Subject.Age, girl: Subject.Gender, reversible encephalopathy syndrome: Effect, consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin: Treatment, acute myelogenous leukemia: Treatment.Disorder, idarubicin: Treatment.Drug, BH-AC: Treatment.Drug, idarubicin: Combination.Drug, BH-AC: Combination.Drug) 